152 related articles for article (PubMed ID: 36622275)
21. Clinicopathological and prognostic values of MET expression in pancreatic adenocarcinoma based on bioinformatics analysis.
Yao Y; Zhan R; Gong C; Lv J; Lu X
Medicine (Baltimore); 2023 Oct; 102(41):e34656. PubMed ID: 37832054
[TBL] [Abstract][Full Text] [Related]
22. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
Tian C; Li X; Ge C
Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
[TBL] [Abstract][Full Text] [Related]
23. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
24. High expression of RNF169 is associated with poor prognosis in pancreatic adenocarcinoma by regulating tumour immune infiltration.
Wang J; Chen H; Deng Q; Chen Y; Wang Z; Yan Z; Wang Y; Tang H; Liang H; Jiang Y
Front Genet; 2022; 13():1022626. PubMed ID: 36685833
[No Abstract] [Full Text] [Related]
25. LINC01232 Sponges Multiple miRNAs and Its Clinical Significance in Pancreatic Adenocarcinoma Diagnosis and Prognosis.
Du W; Lei C; Wang Y; Ding Y; Tian P
Technol Cancer Res Treat; 2021; 20():1533033820988525. PubMed ID: 33506742
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients.
Cui Z; Du L; Wang J; Li Z; Xu J; Ou S; Li D; Li S; Hu H; Chen G; Wu Z
BMC Cancer; 2022 Dec; 22(1):1354. PubMed ID: 36572856
[TBL] [Abstract][Full Text] [Related]
27. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
Zhang T; Sheng P; Jiang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396
[TBL] [Abstract][Full Text] [Related]
28. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.
You W; Ke J; Chen Y; Cai Z; Huang ZP; Hu P; Wu X
Front Immunol; 2022; 13():864244. PubMed ID: 35720314
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma.
Gong Q; Dong Q; Zhong B; Zhang T; Cao D; Zhang Y; Ma D; Cai X; Li Z
J Clin Lab Anal; 2022 Dec; 36(12):e24784. PubMed ID: 36408702
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma.
Duan Y; Du Y; Mu Y; Gu Z; Wang C
Front Mol Biosci; 2022; 9():1096679. PubMed ID: 36589239
[No Abstract] [Full Text] [Related]
31. Combined Evaluation of mRNA and Protein Expression, Promoter Methylation, and Immune Infiltration of UBE2I in Pan-Digestive System Tumors.
Huang S; Wang X; Luo K; Zhang X; Liu Z; Li R
Oxid Med Cell Longev; 2022; 2022():1129062. PubMed ID: 36193060
[TBL] [Abstract][Full Text] [Related]
32. Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer.
Yin L; Xiao L; Gao Y; Wang G; Gao H; Peng Y; Zhu X; Wei J; Miao Y; Jiang K; Lu Z
Med Oncol; 2020 Apr; 37(5):46. PubMed ID: 32277286
[TBL] [Abstract][Full Text] [Related]
33. AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas.
Xu H; Mao J; Yang X; Chen F; Song Z; Fei J; Chen W; Zhong Z; Wang X
Mol Med Rep; 2020 Nov; 22(5):4329-4339. PubMed ID: 33000197
[TBL] [Abstract][Full Text] [Related]
34. The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma.
Li F; Zhang P
Comput Math Methods Med; 2021; 2021():8715823. PubMed ID: 34840598
[TBL] [Abstract][Full Text] [Related]
35. PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma.
Liang X; Fu Z; Tang L; Zheng M; Chen D; Liu A; Shi L; Yang L; Shao C; Dong X
BMC Gastroenterol; 2023 Jan; 23(1):2. PubMed ID: 36600208
[TBL] [Abstract][Full Text] [Related]
36. KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma.
Li Y; Su Z; Wei B; Liang Z
Int J Gen Med; 2021; 14():2677-2694. PubMed ID: 34188523
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma.
Duan Y; Du Y; Gu Z; Zheng X; Wang C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
[TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
39. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
40. Deoxythymidylate kinase (DTYMK) participates in cell cycle arrest to promote pancreatic adenocarcinoma progression regulated by miR-491-5p through TP53 and is associated with tumor immune infiltration.
Bao W; Yang H; Zhou S; Huang F; Wei Z; Peng Z
J Gastrointest Oncol; 2023 Jun; 14(3):1546-1559. PubMed ID: 37435228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
